Jump to content

Search the Community

Showing results for tags 'genetic testing'.

More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


    • Announcements, meetings and other resources
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...

Date Created

  • Start


Last Updated

  • Start


Filter by number of...

Found 3 results

  1. "A new study reported today in the New England Journal of Medicine is suggesting that every man with metastatic prostate cancer (regardless of his age or family history) should be tested for certain particular inherited mutations. The mutations in question are the ones that affect a man’s capacity for DNA repair, e.g., BRCA2, ATM, CHEK2, BRCA1, RAD51D, and PALB2................. Detailed genetic and similar testing of men with advanced forms of prostate cancer [may] be able to optimize the quality of their treatment and their likely outcomes. Such testing may also help us to avoid the unnecessary, inappropriate, and expensive treatment of men with types of therapy that are highly unlikely to work for them as individuals. It will undoubtedly take some time before all this becomes “standard practice” outside the major academic medical centers, but it is also clear that any patient with an advanced form of prostate cancer (M0 or M1 disease, or castration-resistant disease — whether metastatic or not) should be asking his doctors whether such testing is appropriate in his particular case." Click on this link to read the New Prostate Cancer Infolink's take on this research. The link mentioned in the article to a blog post by the Memorial Sloan-Kettering Cancer Center is also worth reading.
  2. "The past years have seen lots of new drugs and developments. This year there has been a pause whilst working out issues of cross resistance and trying to figure out the differences between abiraterone and enzalutamide." Click on this link to view a video of the highlights from the sessions on prostate cancer at ASCO 2016.
  3. A large international study has found that 90 percent of men with advanced prostate cancer have some kind of genetic anomaly that could influence treatment. Inherited defects in DNA repair genes are prevalent in advanced prostate cancer patients regardless of family history, and are associated with poorer responses to hormonal therapy and shorter survival times. Click on this link to read about this study. Click on this link to read a further article in the Prostate Cancer Foundation's NewsPulse newsletter about the study.
  • Create New...